Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis

NCT00168701 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT00168701
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00168701 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy and Safety of BG00012 in Subjects With Relapsing-Remitting Multiple Sclerosis
Lead sponsor
Biogen
Phase
Phase 2
Overall status
Completed
Start date
October 1, 2004
Completion date
March 31, 2006
Enrollment
260 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis